Evidence map›Paper›PMID 26155119›Full record

ArticleCentral-European journal of immunology2014

Recombinant human interleukin receptor antagonist influences serum chemokines in patients with rheumatoid arthritis.

Jun Bao, Wei Liu, Yi-Xiao Bao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Central-European journal of immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jun BaoDepartment of Paediatrics, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China ; Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, PR China.
Wei LiuDepartment of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, PR China.
Yi-Xiao BaoDepartment of Paediatrics, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
Second Military Medical University · CNXinHua Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the serum expressions of chemokines CCL2 and CCL3 in patients with rheumatoid arthritis (RA) who were treated with recombinant human interleukin 1 (IL-1) receptor antagonist (IL-1Ra). MATERIAL AND

methodsSerum CCL2 and CCL3 were determined using an enzyme-linked immunosorbent assay in 54 active RA patients before and after treatment with IL-1Ra or a placebo, as well as 36 healthy controls.

resultsCompared with the healthy controls, all the 54 RA patients exhibited higher serum CCL2 and CCL3 before and after treatment (p < 0.05). However, patients who had a good response to IL-1Ra treatment had significantly lower mean changes in the serum CCL2 and CCL3 levels from baseline to the last injection than IL-1Ra non-responders (p < 0.01).

conclusionsCCL2 and CCL3 may be useful efficacy markers of IL-1Ra treatment.

Indexed as

arthritischemokinesdrug therapyinterleukin-1 receptor antagonist proteinrheumatoid

Identifiers

PMID26155119
PMCPMC4440034
OpenAlexW2182294311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.